Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis

Table 1

Main characteristics of 14 studies included in the meta-analysis.

Study

Year

Country

Cancer type

Number

Gene (+/-) no.

Detection method

Tumor stage

Lymphatic metastasis

Analysis method

Survival analysis

HR statistic

Hazard ratios (95% CI)

NOS scale

I+II/III+IV

Yes/no

Orlando et al. [6]

2018

Italy

MB

51

19/32

RT-qPCR

NR

NR

NR

OS

Rep

4.26 (2.23, 15.39)

7

Zhu et al. [7]

2018

China

HCC

96

58/38

IHC

59/37

40/56

NR

OS, MFS

Rep

1.46 (0.47, 2.93); 1.04 (1.01, 1.09)

8

Pan et al. [9]

2017

Taiwan, China

AC

156

39/82

RT-qPCR

84/37

NR

NR

OS

Rep

0.36 (0.27, 1.66)

7

Gezgin et al. [10]

2017

Netherlands

UM

64

29/35

Microarray

41/23

37/17

NR

OS

SC

1.98 (0.96, 4.08)

7

Field et al. [11]

2016

Netherlands

UM

203

51/152

RT-qPCR and RNA-Seq

NR

NR

MA

OS, MFS

SC

2.33 (1.83, 4.19); 2.51 (1.71, 7.14)

7

Oyama et al. [8]

2016

Japan

HCC

100

27/73

RT-qPCR

57/43

NR

NR

OS, DFS

SC

1.28 (0.82, 1.98); 1.42 (0.92, 2.21)

7

Zhang et al. [12]

2016

USA

HGSC

576

288/288

Microarray

NR

NR

NR

OS, DFS

SC

1.70 (1.42, 2.04); 1.54 (1.28, 1.86)

8

Iura et al.[13]

2015

Japan

MLS

79

44/35

IHC

NR

NR

MA

OS, DFS

SC

1.60 (0.44, 5.89); 1.93 (0.73, 5.07)

6

Mitsuhashi et al.[14]

2014

Japan

DLBCL

160

21/139

IHC

75/85

NR

UA

OS, PFS

Rep

1.89 (0.7, 4.34); 2.40 (1.12, 4.67)

7

Tan et al.[15]

2012

China

Osteosarcoma

95

32/63

IHC

84/10

23/72

NR

OS, MFS

Rep

1.93 (1.08, 3.43); 2.76 (1.65, 4.61)

8

Dyrskjot et al. [16]

2012

Denmark

BC

349

71/278

RT-qPCR

78/253

NR

UA

PFS

Rep

0.61 (0.08, 4.61)

7

Epping et al.[17]

2008

Netherlands

BCA

295

98/197

RT-qPCR

NR

NR

MA

OS, MFS

SC

2.31 (1.43, 3.72); 1.99 (1.33, 2.99)

8

Doolan et al.[18]

2008

Ireland

BCA

103

55/48

RT-qPCR

50/53

58/45

UA

OS, DFS

SC

2.00 (0.69, 5.75); 3.04 (1.57, 5.88)

8

Oberthuer et al.[19]

2004

Germany

Neuroblastoma

94

74/20

Northern blotting

31/63

NR

NR

PFS

SC

1.24 (0.30, 5.17)

6

MB: medulloblastoma; HCC: hepatocellular carcinoma; AC: adenocarcinoma; UM: uveal melanoma; HGSC: high-grade serous cancer; MLS: myxoid liposarcoma; DLBCL: diffuse large B-cell lymphoma; BC: bladder cancer; BCA: breast carcinoma; IHC: immunohistochemistry; RT-qPCR: quantitative real-time PCR; NR: not reported; UA: univariate analysis; MA: multivariate analysis; OS: overall survival; MFS: metastasis-free survival; DFS: disease-free survival; PFS: progression-free survival; HR: hazard ratio; Rep: reported; SC: survival curve; CI: confidence interval; NOS: Newcastle-Ottawa scores.